Eton Pharmaceuticals, Inc

(NASDAQ:ETON)

Latest On Eton Pharmaceuticals, Inc (ETON):

Date/Time Type Description Signal Details
2023-05-11 19:30 ESTNewsEton Pharmaceuticals GAAP EPS of -$0.10 beats by $0.04, revenue of $5.3M beats by $0.74MN/A
2023-05-11 19:30 ESTNewsEton Pharmaceuticals, Inc. (ETON) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 04:34 ESTNewsEton Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-20 12:57 ESTNewsEton Pharmaceuticals Has Some Potential As A Speculative PlayN/A
2023-03-17 08:31 ESTNewsEton Pharmaceuticals, Inc. (ETON) Q4 2022 Earnings Call TranscriptN/A
2023-03-16 17:33 ESTNewsEton Pharmaceuticals GAAP EPS of $0.04 beats by $0.03, revenue of $8.5M misses by $0.62MN/A
2023-03-16 02:22 ESTNewsEton Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-03-15 10:56 ESTNewsEton acquires Tulex's pediatric rare disease drug ET-600N/A
2023-01-11 09:58 ESTNewsEton says FDA accepted resubmitted NDA for methanol poisoning candidateN/A
2022-12-18 06:29 ESTNewsEton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease PortfolioN/A
2022-11-11 09:37 ESTNewsEton Pharmaceuticals, Inc. (ETON) Q3 2022 Earnings Call TranscriptN/A
2022-11-10 16:33 ESTNewsEton Pharmaceuticals GAAP EPS of -$0.12, revenue of $3.22MN/A
2022-09-14 04:19 ESTNewsEton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrousN/A
2022-08-17 00:40 ESTNewsEton hits 52-week low on patent infringement ruling over generic Cysteine injectionN/A
2022-08-14 22:42 ESTNewsEton Pharmaceuticals: An Evolving 'Sum Of The Parts' StoryN/A
2022-08-12 18:52 ESTNewsEton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-12 02:08 ESTNewsEton Pharmaceuticals GAAP EPS of -$0.06 misses by $0.09, revenue of $7.4M misses by $0.36MN/A
2022-08-11 09:11 ESTNewsEton Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-18 11:34 ESTNewsEton Pharma jumps 20% on FDA approval of seizure therapyN/A
2022-06-25 01:28 ESTNewsEton Pharmaceuticals sells hospital products to Dr. Reddy’s for up to $50MN/A
2022-05-27 19:52 ESTNewsEton Pharmaceuticals down 10% after hours following partner Complete Response LetterN/A
2022-05-17 06:20 ESTNewsEton Pharmaceuticals (ETON) Investor Presentation - SlideshowN/A
2022-05-13 12:51 ESTNewsEton Pharmaceuticals, Inc.'s (ETON) CEO Sean Brynjelsen on Q1 2021 Results - Earnings Call TranscriptN/A
2022-05-12 17:03 ESTNewsEton Pharmaceuticals GAAP EPS of -$0.21, revenue of $2.18MN/A
2022-05-11 22:56 ESTNewsEton Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-11 20:25 ESTNewsEton Pharma gains on FDA approval for Elcys genericN/A
2022-04-11 20:25 ESTNewsJames Gruber joins Eton Pharmaceuticals as CFON/A
2022-03-17 08:20 ESTNewsEton Pharmaceuticals GAAP EPS of $0.04 misses by $0.01, revenue of $6.09M misses by $1.47MN/A
2022-03-17 08:20 ESTNewsEton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-15 23:30 ESTNewsEton Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-03-14 10:21 ESTNewsEton Pharmaceuticals, XGen launch low blood pressure drug RezipresN/A
2021-11-16 20:12 ESTNewsEton Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-16 20:12 ESTNewsWarning: ETON is at high risk of performing badlyN/A
2021-11-16 00:39 ESTNewsEton Pharmaceuticals in pact with Tolmar to jointly promote ALKINDI SPRINKLEN/A
2021-11-16 00:37 ESTNewsEton Pharmaceuticals EPS misses by $0.10, misses on revenueN/A
2021-11-16 00:37 ESTNewsEton Pharmaceuticals' (ETON) CEO Sean Brynjelsen on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-08 11:19 ESTNewsEton Pharma granted FDA approval for seizure and migraine therapyN/A
2021-10-28 20:59 ESTNewsEton Pharma acquires marketing rights to generic version of CarbagluN/A
2021-09-03 15:13 ESTNewsAnother Look At Eton PharmaceuticalsN/A
2021-08-17 13:01 ESTNewsEton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-16 17:26 ESTNewsEton Pharma urged to address misleading claims linked to Alkindi SprinkleN/A
2021-08-16 17:25 ESTNewsEton Pharmaceuticals EPS beats by $0.06, misses on revenueN/A
2021-08-15 22:48 ESTNewsEton Pharmaceuticals Q2 2021 Earnings PreviewN/A
2021-08-10 03:34 ESTNewsEton shares drop 18% on topiramate FDA action date delayN/A
2021-08-09 07:19 ESTNewsFDA decision on Eton's topiramate delayed to NovemberN/A
2021-08-06 23:12 ESTNewsMVST, MDRX, ETON and GDS among after hours moversN/A
2021-07-21 08:02 ESTNewsFDA declines to approve Eton Pharmaceuticals' methanol poisoning treatmentN/A
2021-07-21 07:47 ESTNewsStocks To Watch: FOMC Takes Center Stage, Hedge Funds Pitch And E3N/A
2021-07-21 07:44 ESTNewsEton Pharma wins FDA approval for RezipresN/A
2021-07-21 07:44 ESTNewsEton Pharmaceuticals acquires U.S. and Canadian rights to ZENEO hydrocortisone autoinjectorN/A

About Eton Pharmaceuticals, Inc (ETON):

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. The company offers Biorphen, a phenylephrine hydrochloride injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. It also develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-203, which is injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101 and ET-104, which are oral liquid product candidates for neurological indications; DS-300 and DS-100, which are injectable product candidates; and ET-105, a lamotrigine for oral suspension. Eton Pharmaceuticals, Inc. was founded in 2017 and is based in Deer Park, Illinois.

ETON Quotes by TradingView

See Advanced Chart

General

  • Name Eton Pharmaceuticals, Inc
  • Symbol ETON
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 17
  • Fiscal Year EndDecember
  • IPO Date2018-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.etonpharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 4320.52
  • Price/Book (Most Recent Quarter) 12.5
  • Enterprise Value Revenue 4656.31
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $0.24
  • Next Year EPS Estimate $0.30
  • Next Quarter EPS Estimate -$0.24
  • Operating Margin -69515%
  • Return on Assets -78%
  • Return on Equity -213%
  • Revenue 39000
  • Earnings Per Share -$3.07
  • Revenue Per Share $0
  • Gross Profit -247000
  • Quarterly Earnings Growth -82.4%
View More

Highlights

  • Market Capitalization 200.63 million
  • EBITDA -15345000
  • PE Ratio -87.55
  • Analyst Target Price $13.5
  • Book Value Per Share $0.64
View More

Share Statistics

  • Shares Outstanding 24.41 million
  • Shares Float 13.73 million
  • % Held by Insiders 2803%
  • % Held by Institutions 29.14%
  • Shares Short 788868
  • Shares Short Prior Month 807494
  • Short Ratio 4.72
  • Short % of Float 5%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.23
  • 52 Week High $10.3
  • 52 Week Low $2.75
  • 50 Day Moving Average 8.8
  • 200 Day Moving Average 8.15
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Eton Pharmaceuticals, Inc (ETON) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Eton Pharmaceuticals, Inc (ETON) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A-$0.32-$0.26-23.08%
2020-09-302020-11-12$-161000-$0.31-$0.25-22.38%
2020-06-302020-08-12$N/A-$0.23-$0.2611.54%
2020-03-312020-05-14$99000-$0.50-$0.22-123.91%
2019-12-312020-03-05$459000-$0.15-$0.2643.03%
2019-09-302019-11-14$N/A-$0.28-$0.25-13.5%
2019-06-302019-08-06$N/A-$0.18-$0.2834.55%
2019-03-312019-05-07$500000-$0.42
2018-12-312019-03-25$N/A-$2.24
2018-09-302018-12-20$N/A-$2.24

Eton Pharmaceuticals, Inc (ETON) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Eton Pharmaceuticals, Inc (ETON) Chart:

Eton Pharmaceuticals, Inc (ETON) News:

Below you will find a list of latest news for Eton Pharmaceuticals, Inc (ETON) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Eton Pharmaceuticals, Inc (ETON) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.52.25CALL0 4123.19TRUE00
2024-05-1750.05CALL0 2660FALSE00
2024-05-177.50.05CALL0 10FALSE00
2024-05-17100.1CALL0 1520FALSE00
2024-05-172.50PUT0 00FALSE00
2024-05-1750PUT0 0211.34TRUE00
2024-05-177.50PUT0 0387.58TRUE00
2024-05-17100PUT0 0397.8TRUE00
2024-06-212.50CALL0 00TRUE00
2024-06-2150CALL0 00FALSE00
2024-06-212.50PUT0 00FALSE00
2024-06-2150PUT0 00TRUE00
2024-08-162.51.3CALL0 10147.35TRUE00
2024-08-1650.2CALL0 160FALSE00
2024-08-167.50.05CALL0 3580FALSE00
2024-08-162.50PUT0 0139.37FALSE00
2024-08-1651.5PUT0 12140TRUE00
2024-08-167.50PUT0 0172.29TRUE00
2024-11-152.51.51CALL0 11115.55TRUE00
2024-11-1550CALL0 0113.45FALSE00
2024-11-157.50.11CALL0 60FALSE00
2024-11-152.50PUT0 0127.23FALSE00
2024-11-1550PUT0 062.5TRUE00
2024-11-157.50PUT0 0157.02TRUE00

Latest ETON Trades:

Date Shares Price
Jun 13, 2022 5:36 PM EST2$2.885
Jun 13, 2022 5:47 PM EST4$2.885
Jun 13, 2022 6:38 PM EST13$2.9
Jun 13, 2022 7:24 PM EST100$2.9
Jun 13, 2022 7:25 PM EST100$2.86

Eton Pharmaceuticals, Inc (ETON) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220010937/0001493152-20-010937-index.htm
2019-12-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1710340/000000000019016252/0000000000-19-016252-index.htm
2020-05-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1710340/000000000020003885/0000000000-20-003885-index.htm
2020-05-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1710340/000000000020004688/0000000000-20-004688-index.htm
2020-08-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1710340/000000000020007104/0000000000-20-007104-index.htm
2018-11-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000089914018000602/0000899140-18-000602-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058316/0001209191-18-058316-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058318/0001209191-18-058318-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058320/0001209191-18-058320-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058321/0001209191-18-058321-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058324/0001209191-18-058324-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058325/0001209191-18-058325-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058821/0001209191-18-058821-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058822/0001209191-18-058822-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058824/0001209191-18-058824-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058825/0001209191-18-058825-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058826/0001209191-18-058826-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058827/0001209191-18-058827-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018103/0001209191-19-018103-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018106/0001209191-19-018106-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018109/0001209191-19-018109-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018114/0001209191-19-018114-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018118/0001209191-19-018118-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018122/0001209191-19-018122-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119032054/0001209191-19-032054-index.htm
2019-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119045498/0001209191-19-045498-index.htm
2019-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119045738/0001209191-19-045738-index.htm
2018-11-08CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1710340/000135445718000454/0001354457-18-000454-index.htm
2017-06-28DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315217007275/0001493152-17-007275-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315218015806/0001493152-18-015806-index.htm
2018-11-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1710340/000149315218016669/0001493152-18-016669-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315218017722/0001493152-18-017722-index.htm
2018-12-2010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315218017724/0001493152-18-017724-index.htm
2019-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219000907/0001493152-19-000907-index.htm
2019-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219001663/0001493152-19-001663-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315219001718/0001493152-19-001718-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219002230/0001493152-19-002230-index.htm
2019-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219003813/0001493152-19-003813-index.htm
2019-03-2510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1710340/000149315219003817/0001493152-19-003817-index.htm
2019-03-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1710340/000149315219004108/0001493152-19-004108-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1710340/000149315219006004/0001493152-19-006004-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1710340/000149315219006005/0001493152-19-006005-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219006515/0001493152-19-006515-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315219006526/0001493152-19-006526-index.htm
2019-05-24SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315219008254/0001493152-19-008254-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219009066/0001493152-19-009066-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219009127/0001493152-19-009127-index.htm
2019-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219010573/0001493152-19-010573-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219011467/0001493152-19-011467-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219011725/0001493152-19-011725-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315219011727/0001493152-19-011727-index.htm
2019-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219012932/0001493152-19-012932-index.htm
2019-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219015787/0001493152-19-015787-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219017479/0001493152-19-017479-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315219017499/0001493152-19-017499-index.htm
2019-12-02S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000149315219018638/0001493152-19-018638-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219018669/0001493152-19-018669-index.htm
2019-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219019062/0001493152-19-019062-index.htm
2019-12-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1710340/000149315219019077/0001493152-19-019077-index.htm
2020-01-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220000810/0001493152-20-000810-index.htm
2020-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220001575/0001493152-20-001575-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220002532/0001493152-20-002532-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220002695/0001493152-20-002695-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1710340/000149315220003451/0001493152-20-003451-index.htm
2020-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220003486/0001493152-20-003486-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004052/0001493152-20-004052-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004053/0001493152-20-004053-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004056/0001493152-20-004056-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004058/0001493152-20-004058-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004059/0001493152-20-004059-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004062/0001493152-20-004062-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004113/0001493152-20-004113-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004191/0001493152-20-004191-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220005035/0001493152-20-005035-index.htm
2020-03-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220005038/0001493152-20-005038-index.htm
2020-04-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220005927/0001493152-20-005927-index.htm
2020-04-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220005929/0001493152-20-005929-index.htm
2020-04-08DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220006039/0001493152-20-006039-index.htm
2020-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220006934/0001493152-20-006934-index.htm
2020-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1710340/000149315220006939/0001493152-20-006939-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220007595/0001493152-20-007595-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220007843/0001493152-20-007843-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220007957/0001493152-20-007957-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220008752/0001493152-20-008752-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220008763/0001493152-20-008763-index.htm
2020-05-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1710340/000149315220009223/0001493152-20-009223-index.htm
2020-05-2110-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1710340/000149315220009627/0001493152-20-009627-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220010937/0001493152-20-010937-index.htm
2020-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220014011/0001493152-20-014011-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220014213/0001493152-20-014213-index.htm
2020-07-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000149315220014330/0001493152-20-014330-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220014335/0001493152-20-014335-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220015198/0001493152-20-015198-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220015303/0001493152-20-015303-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220015336/0001493152-20-015336-index.htm
2020-08-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1710340/000149315220016594/0001493152-20-016594-index.htm
2020-08-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220016975/0001493152-20-016975-index.htm
2020-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220017873/0001493152-20-017873-index.htm
2020-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220018322/0001493152-20-018322-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220018576/0001493152-20-018576-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019035/0001493152-20-019035-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019121/0001493152-20-019121-index.htm
2020-10-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220019347/0001493152-20-019347-index.htm
2020-10-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019406/0001493152-20-019406-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019467/0001493152-20-019467-index.htm
2020-10-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220019503/0001493152-20-019503-index.htm
2020-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019583/0001493152-20-019583-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019587/0001493152-20-019587-index.htm
2018-03-20DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1710340/000161577418002013/0001615774-18-002013-index.htm
2018-06-28DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1710340/000161577418005879/0001615774-18-005879-index.htm
2018-08-10S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/0001615774-18-007833-index.htm
2018-09-25S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418009956/0001615774-18-009956-index.htm
2018-09-28FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1710340/000161577418010167/0001615774-18-010167-index.htm
2018-10-18S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/0001615774-18-011027-index.htm
2018-10-31S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418011677/0001615774-18-011677-index.htm
2018-11-05S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418012090/0001615774-18-012090-index.htm
2018-11-088-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1710340/000161577418012296/0001615774-18-012296-index.htm
2018-11-13424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1710340/000161577418012575/0001615774-18-012575-index.htm
2018-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000161577418013052/0001615774-18-013052-index.htm
2018-11-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1710340/000161577418013060/0001615774-18-013060-index.htm
2018-11-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1710340/999999999518002850/9999999995-18-002850-index.htm
2019-12-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1710340/999999999519002824/9999999995-19-002824-index.htm
2020-08-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1710340/999999999520002245/9999999995-20-002245-index.htm
2018-11-09CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1710340/999999999718008960/9999999997-18-008960-index.htm

Eton Pharmaceuticals, Inc (ETON) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eton Pharmaceuticals, Inc (ETON). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2803%
Institutional Ownership: 2914%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-11-15MARK L BAUMDirectorBuy10,000.006.0060,000.0010,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058821/0001209191-18-058821-index.htm
2018-11-15SEAN BRYNJELSENPresident & CEOBuy10,000.006.0060,000.001,010,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058826/0001209191-18-058826-index.htm
2019-05-20SEAN BRYNJELSENPresident & CEOBuy1,400.007.7810,894.801,011,400.00https://www.sec.gov/Archives/edgar/data/1710340/000120919119032054/0001209191-19-032054-index.htm
2019-05-21SEAN BRYNJELSENPresident & CEOBuy8,600.007.9668,431.061,020,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919119032054/0001209191-19-032054-index.htm
2019-08-13SEAN BRYNJELSENPresident & CEOBuy5,000.006.1530,750.001,025,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919119045738/0001209191-19-045738-index.htm
2020-10-16Opaleye Management Inc.10% Share HolderBuy15,000.007.00105,000.00155,000.00https://www.sec.gov/Archives/edgar/data/1710340/000149315220019587/0001493152-20-019587-index.htm
2020-10-16Opaleye Management Inc.10% Share HolderBuy385,000.007.002,695,000.003,885,000.00https://www.sec.gov/Archives/edgar/data/1710340/000149315220019587/0001493152-20-019587-index.htm
2018-11-15William Wilson TroutmanCFO, Treasurer & SecretaryBuy5,000.006.0030,000.005,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058822/0001209191-18-058822-index.htm
2018-11-15NORBERT G RIEDELDirectorBuy5,000.006.0030,000.0059,745.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058824/0001209191-18-058824-index.htm
2018-11-15PAUL V MAIERDirectorBuy5,000.006.0030,000.0059,745.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058825/0001209191-18-058825-index.htm
2018-11-15CHARLES J CASAMENTODirectorBuy5,000.006.0030,000.0068,420.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058827/0001209191-18-058827-index.htm
2019-08-09CHARLES J CASAMENTODirectorBuy3,500.006.1121,369.9571,920.00https://www.sec.gov/Archives/edgar/data/1710340/000120919119045498/0001209191-19-045498-index.htm